Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

[Incretin modulators, a new perspective in diabetes mellitus treatment].

Lupaşcu FG, Geangalău IM, Pânzariu A, Profire L.

Rev Med Chir Soc Med Nat Iasi. 2012 Apr-Jun;116(2):630-4. Romanian.

PMID:
23077965
2.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
3.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
4.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
5.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
6.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
7.
8.

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. Review.

PMID:
18054732
9.

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

Freeman JS.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S12-9. doi: 10.3949/ccjm.76.s5.03. Review.

10.

Incretin therapy and its effect on body weight in patients with diabetes.

Lind M.

Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Review.

PMID:
22613745
11.

The pathophysiologic role of incretins.

Freeman JS.

J Am Osteopath Assoc. 2007 May;107 Suppl:S6-9. Review.

PMID:
17724014
12.

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Davidson JA, Parente EB, Gross JL.

Arq Bras Endocrinol Metabol. 2008 Aug;52(6):1039-49. Review.

13.

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.

Namba M, Katsuno T, Kusunoki Y, Matsuo T, Miuchi M, Miyagawa J.

Clin Exp Nephrol. 2013 Feb;17(1):10-5. doi: 10.1007/s10157-012-0709-0. Epub 2012 Nov 8. Review.

PMID:
23135865
14.

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C.

Therapie. 2007 Jul-Aug;62(4):293-310. Epub 2007 Nov 6. Review.

PMID:
17983555
15.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
16.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
17.
18.

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.

Triplitt C, Wright A, Chiquette E.

Pharmacotherapy. 2006 Mar;26(3):360-74. Review.

PMID:
16503716
19.

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.

Creutzfeldt W.

Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S288-303. Review.

PMID:
11460578
20.

Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.

Martin CL.

Diabetes Educ. 2008 May-Jun;34 Suppl 3:66S-72S. doi: 10.1177/0145721708319238.

PMID:
18525067

Supplemental Content

Support Center